GOV.UK

UK first in Europe to authorise orforglipron for weight management and type 2 diabetes

Independent

Foundayo: New once-daily weight loss pill now available in pharmacies across UK

Eli Lilly and Company

FDA approves Lilly's Foundayo™ (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions

GB News

Britain first in Europe to launch daily weight-loss pill

Nice

Orforglipron for managing overweight and obesity [ID6516]

Weight-loss drugs aren't a magic bullet. Lifestyle changes are key to lasting health

Most obesity drugs do not improve quality of life or heart health

Metaculus

Glp 1 Based Drug Approval By 2029

Morgan Stanley

TD Securities

Goldman Sachs

J.P. Morgan

UBS Global Wealth Management

CNBC

National Institutes of Health (NIH)

TradingView

GlobalData

Edgen

Gabelli

Fortune Business Insights

BCC Research

UPS Healthcare

Inizio Ignite

Research and Markets

HiQual Insights

Len Yaffe

Teneo

Harvest ETFs

"The obesity therapeutics market is projected for significant expansion, targeting $20.84 billion by 2033 with a compound annual growth rate of 20.6%."

"The global anti-obesity drugs market size was valued at USD 4.51 billion in 2023 and is projected to grow from USD 6.15 billion in 2024 to USD 37.94 billion by 2032, exhibiting a CAGR of 25.5% during the forecast period (2024-2032)."

"We estimate about 12-15 million patients will be using GLP-1 drugs by 2030 across both indications, which translates to the market growing from ~$30B today to ~$80B by 2030."

"Goldman Sachs Research forecasts the global market to reach $95 billion by 2030 — lower than its previous estimate of $130 billion."

"The global market for GLP-1 Receptor Agonist was valued at US$51.9 Billion in 2024 and is projected to reach US$137.4 Billion by 2030."

"Global GLP-1 sales in 2030 could reach US$139 billion, up from our US$101 billion forecast a little over a year ago."

"This [GLP-1 model forecast] translates into $126bn sales by 2029, a 2023-2029 sales CAGR of 30%."

"According to BCC Research’s Global GLP-1 Analogues Market report, the market was valued at $54.8 billion in 2024 and is projected to reach $268.4 billion by 2030."

"J.P. Morgan Global Research forecasts that the global incretin market, which includes GLP-1s, will reach $200 billion by 2030."

Will Annual Global Sales of GLP-1-Based Anti-Obesity and Diabetes Drugs Exceed $100B by 2028?

Orforglipron, sold under the brand name Foundayo and manufactured by Eli Lilly, became available in UK pharmacies in August 2026, making the UK the first country in Europe to approve and dispense the once-daily weight-loss pill.

Guardian

Orforglipron, sold under the brand name Foundayo and manufactured by Eli Lilly, became available in UK pharmacies in August 2026, making the UK the first country in Europe to approve and dispense the once-daily weight-loss pill.

The Medicines and Healthcare products Regulatory Agency authorized Foundayo for adults with a BMI of 30 or above, or between 27 and 30 with at least one weight-related condition, as well as for improving blood sugar control in poorly controlled type 2 diabetes.

The Medicines and Healthcare products Regulatory Agency authorized Foundayo for adults with a BMI of 30 or above, or between 27 and 30 with at least one weight-related condition, as well as for improving blood sugar control in poorly controlled type 2 diabetes.

Foundayo is initially available only via private prescription in the UK. Eli Lilly said it is working with the National Institute for Health and Care Excellence, which has an expected guidance publication date of Nov. 18, 2026, on a potential NHS rollout.

Foundayo is initially available only via private prescription in the UK. Eli Lilly said it is working with the National Institute for Health and Care Excellence, which has an expected guidance publication date of Nov. 18, 2026, on a potential NHS rollout.

In the ATTAIN-1 Phase 3 clinical trial, participants taking the highest dose of Foundayo who remained on treatment lost an average of 27.3 pounds, compared to 2.2 pounds for those on a placebo, over 72 weeks.

In the ATTAIN-1 Phase 3 clinical trial, participants taking the highest dose of Foundayo who remained on treatment lost an average of 27.3 pounds, compared to 2.2 pounds for those on a placebo, over 72 weeks.

The pill is taken once daily at any time without food or water restrictions. Dosage begins at 0.8 mg and escalates through five further stages to 17.2 mg, with a minimum of one month required at each dose level.

The pill is taken once daily at any time without food or water restrictions. Dosage begins at 0.8 mg and escalates through five further stages to 17.2 mg, with a minimum of one month required at each dose level.

Health officials and pharmacists have warned that pill-form weight-loss treatments are easier for criminals to counterfeit than injectables. The MHRA previously seized £250,000 worth of unlicensed weight-loss products from a factory in Northampton.

Health officials and pharmacists have warned that pill-form weight-loss treatments are easier for criminals to counterfeit than injectables. The MHRA previously seized £250,000 worth of unlicensed weight-loss products from a factory in Northampton.

Eli Lilly launches oral weight-loss pill Foundayo in UK

Eli Lilly launches oral weight-loss pill Foundayo in UK

The Controversies

Edgen

Insights

Gabelli

Sachs

Markets

Management

Research

Morgan

Sign Up for Our Free Newsletters
Sign Up for Our Free Newsletters

Eli Lilly launches oral weight-loss pill Foundayo in UK

Eli Lilly launches oral weight-loss pill Foundayo in UK

The Controversies

Edgen

Insights

Gabelli

Sachs

Markets

Management

Research

Morgan

Sign Up for Our Free NewslettersSign Up for Our Free Newsletters

Sign Up for Our Free Newsletters
Sign Up for Our Free Newsletters